Adicet Bio posts updated corporate presentation highlighting allogeneic CAR γδ1 cell therapies

Adicet Bio, Inc.

Presentation dated January 16, 2024 posted to investor.adicetbio.com.
Focus on allogeneic CAR γδ1 cell therapies for autoimmune diseases and cancer.
No clinical data, financial updates, or pipeline milestones disclosed in the filing.

item 7.01 item 9.01

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-004403

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.